PROTEOMICS ALLIANCE FOR CANCER

癌症蛋白质组学联盟

• 批准号: 7359135
• 负责人: GILBERT S OMENN
• 金额: $ 8.13万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-01 至 2007-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7359135
• 关键词: PROTEOMICS; ALLIANCE; CANCER

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Proteomics Alliance for Cancer (PAC) is supported by the Michigan Life Sciences Corridor (MLSC)/Michigan Economic Development Corporation, and affiliated with the UM NCRR Center The Proteomics Alliance for Cancer has brought together key laboratories in the cancer proteomics domain at the University of Michigan, Van Andel Research Institute, local firms, MLSC Core Technology Alliance, and the UM NCRR Center. The PAC has demonstrated the usefulness for clinical studies of the Cy3/Cy5 double-labeling of paired clinical specimens (before and after treatment, or before and after development of complications), combined with our 3-dimensional fractionation and mass spec analysis scheme. Novel findings were obtained for graft-versus-host disease after bone marrow transplantation, a treatment for certain kinds of cancers. PAC served as the beta-site for the new Beckman-Coulter PF 2D proteomics equipment and as one of several beta-sites for the new Agilent immuno-affinity column for depletion of the six most abundant proteins in plasma/serum. We made major contributions to the improvements of these new products and have had the benefit of early use of the equipment. Both companies have introduced these products commercially. We concluded that depletion of albumin and several other highly abundant proteins in plasma can markedly improve the resolution and sensitivity of detection of less abundant proteins, including those which may be derived from organs and tissues that are sites of origin of disease processes. We are pursuing the challenging aim of enhancing throughput in liquid-based separation systems. At the same time, we are utilizing the existing LC systems to create 2000 fractions from tumor cell lysates for protein microarrays both at VAI and UM that have promise for diagnostic applications. Substantial progress has been made collaboratively in the Haab lab at Van Andel and the Hanash lab at UM on prostate and lung cancer cell protein microarrays for detection of circulating auto-antibodies against these proteins in the sera of patients with prostate cancer or lung cancer, respectively. These studies have major potential to identify and validate useful biomarkers for earlier diagnosis of these and other cancers.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。癌症蛋白质组学联盟（PAC）由密歇根生命科学走廊（MLSC）/密歇根经济发展公司支持，并隶属于UM NCRR中心癌症蛋白质组学联盟汇集了密歇根大学，货车Andel研究所，当地公司，MLSC核心技术联盟和UM NCRR中心癌症蛋白质组学领域的关键实验室。 PAC已经证明了Cy 3/Cy 5双标记配对临床标本（治疗前后，或并发症发生前后）的临床研究的有用性，结合我们的三维分馏和质谱分析方案。骨髓移植后移植物抗宿主病获得了新的发现，骨髓移植是一种治疗某些癌症的方法。PAC用作新型Beckman-Coulter PF 2D蛋白质组学设备的β位点，并作为新型Agilent免疫亲和柱的几个β位点之一，用于消除血浆/血清中六种最丰富的蛋白质。我们对这些新产品的改进作出了重大贡献，并受益于设备的早期使用。这两家公司都将这些产品推向了市场。我们的结论是，血浆中白蛋白和其他几种高丰度蛋白质的消耗可以显着提高分辨率和灵敏度的检测丰度较低的蛋白质，包括那些可能来自器官和组织的起源的疾病过程的网站。 我们正在追求提高液基分离系统的生产能力这一具有挑战性的目标。与此同时，我们正在利用现有的LC系统从肿瘤细胞裂解物中产生2000个组分，用于VAI和UM的蛋白质微阵列，这些蛋白质微阵列具有诊断应用的前景。货车Andel的Haab实验室和UM的Hanash实验室在前列腺和肺癌细胞蛋白微阵列上合作取得了实质性进展，用于分别检测前列腺癌或肺癌患者血清中针对这些蛋白的循环自身抗体。这些研究有很大的潜力来识别和验证有用的生物标志物，用于这些和其他癌症的早期诊断。